| |
March 18-20, 2024 | Savannah, GA The Fierce TMF Summit is the must-attend event for clinical document management professionals to learn, network and connect. Gain invaluable insights from unique case studies, panels, and workshops, and access the best networking the industry has to offer. Register now and SAVE $300 until February 23 to take your TMF to the next level. Sign up today!
|
|
Today’s Big NewsFeb 13, 2024 |
| By Annalee Armstrong If you ask Pfizer’s chief scientist Mikael Dolsten, M.D., Ph.D., what the next pandemic will be, you may be surprised at the answer. It’s not viral or respiratory, and, in fact, it’s here now. |
|
|
|
By Annalee Armstrong AI drug hunter Exscientia has fired CEO Andrew Hopkins effective immediately after the board determined he had engaged in two personal relationships with employees that were deemed “inappropriate and inconsistent” with company values. |
By Gabrielle Masson Bristol Myers Squibb is offering Roivant's VantAI up to $674 million biobucks in a new partnership aimed at designing molecular glues as small-molecule therapeutics. |
Sponsored by Questex Fierce Life Sciences and Healthcare sit down with biotech, pharma, and healthcare executives at Fierce JPM Week. |
By Max Bayer The frenzy around GLP-1s has changed BioAge’s trajectory, as its one of a select few biotechs with a combo candidate that might enhance weight loss without muscle loss. |
By James Waldron With Big Pharma’s heading into 2024 with a renewed interest in antibody-drug conjugates (ADCs), it’s no surprise that ProfoundBio managed to assemble a who’s who of biotech investors for an oversubscribed series B round. |
By Max Bayer KalVista's oral HAE treatment ambitions were almost dashed a year and a half ago after one midstage candidate fell by the wayside. But a sibling program has tasted victory, nailing primary and key secondary endpoints in a phase 3 trial. |
By Nick Paul Taylor Roche has made a fast U-turn on Repare Therapeutics’ synthetic lethal drug candidate. Days after dosing a phase 2 patient and triggering a $40 million payment, Roche told the oncology biotech that it will hand back the asset following a review of its pipeline and “evolving external factors.” |
By James Waldron Shattack Labs’ pipeline of bifunctional fusion proteins has caught the attention of Ono Pharmaceutical, with the Japanese drug developer penning a $227 million biobucks deal focused on autoimmune and inflammatory diseases. |
By James Waldron LianBio has become the latest biotech to throw in the towel, with the Chinese company announcing that a four-month strategic review has concluded there's no choice but to wind down. |
By Helen Floersh A naturally occurring mutation in T cells that leads to lymphoma can be weaponized to make engineered T-cell therapies more effective against cancer, including melanoma, findings from a new study in mice suggests. |
By Nick Paul Taylor Pfizer won the pharma ad Super Bowl. That’s the conclusion of TV outcomes company EDO, which found Pfizer saw more incremental online activity for its brand than fellow Super Bowl advertiser Astellas after they ran their ads at the big game. |
By Noah Tong Omada executives shared they are expanding upon its GLP-1 Care Track, pushed by the belief that helping patients regain muscle mass is a critical to weight maintenance after tapering off utilization. |
By Fraiser Kansteiner Roughly half a year after Biogen’s $7.3 billion buyout of rare disease specialist Reata Pharmaceuticals, the companies’ blockbuster bid for Reata’s Friedreich’s ataxia (FA) drug Skyclarys is starting to take shape. |
Fierce podcastsDon’t miss an episode |
| | This week on “The Top Line,” we explore the most anticipated drug launches of 2024. Editor-in-Chief Ayla Ellison engages in a conversation with Fierce Pharma Marketing Senior Editor Ben Adams about the drugs likely to launch this year with the most significant sales potential by 2028. |
|
|---|
|
|
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now!
|
|
| Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
| Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
